HER2 and UPAR Cooperativity Contribute to Metastatic Phenotype of HER2-positive Breast Cancer

Overview

Journal Oncoscience

Specialty Oncology

Date 2015 Apr 22

PMID 25897424

Citations 15

Authors

Vineesh Indira Chandran

Serenella Eppenberger-Castori

Thejaswini Venkatesh

Kara Lea Vine

Marie Ranson

Affiliations

Soon will be listed here.

Abstract

Human epidermal growth factor receptor type 2 (HER2)-positive breast carcinoma is highly aggressive and mostly metastatic in nature though curable/manageable in part by molecular targeted therapy. Recent evidence suggests a subtype of cells within HER2-positive breast tumors that concomitantly expresses the urokinase plasminogen activator receptor (uPAR) with inherent stem cell/mesenchymal-like properties promoting tumor cell motility and a metastatic phenotype. This HER-positive/uPAR-positive subtype may be partially responsible for the failure of HER2-targeted treatment strategies. Herein we discuss and substantiate the cumulative preclinical and clinical evidence on HER2-uPAR cooperativity in terms of gene co-amplification and/or mRNA/protein co-overexpression. We then propose a regulatory signaling model that we hypothesize to maintain upregulation and cooperativity between HER2 and uPAR in aggressive breast cancer. An improved understanding of the HER2/uPAR interaction in breast cancer will provide critical biomolecular information that may help better predict disease course and response to therapy.

Citing Articles

Urokinase-Type Plasminogen Activator Receptor (uPAR) in Inflammation and Disease: A Unique Inflammatory Pathway Activator.

Hamada M, Varkoly K, Riyadh O, Beladi R, Munuswamy-Ramanujam G, Rawls A Biomedicines. 2024; 12(6).

PMID: 38927374 PMC: 11201033. DOI: 10.3390/biomedicines12061167.

Prognostic Significance of Microvessel Density in Invasive Ductal Carcinoma of Breast.

Abbasi A, Ghaffarizadeh F, Mojdeganlou H Int J Hematol Oncol Stem Cell Res. 2023; 17(2):100-105.

PMID: 37637763 PMC: 10452950. DOI: 10.18502/ijhoscr.v17i2.12646.

High-throughput optofluidic screening of single B cells identifies novel cross-reactive antibodies as inhibitors of uPAR with antibody-dependent effector functions.

Lourenco A, Chuo S, Bohn M, Hann B, Khan S, Yevalekar N MAbs. 2023; 15(1):2184197.

PMID: 36859773 PMC: 9988344. DOI: 10.1080/19420862.2023.2184197.

Identification of PLAUR-related ceRNA and immune prognostic signature for kidney renal clear cell carcinoma.

Wang Y, Sun Z, Lu S, Zhang X, Xiao C, Li T Front Oncol. 2022; 12:834524.

PMID: 36052236 PMC: 9424644. DOI: 10.3389/fonc.2022.834524.

The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities.

Metrangolo V, Ploug M, Engelholm L Cancers (Basel). 2021; 13(21).

PMID: 34771541 PMC: 8582577. DOI: 10.3390/cancers13215376.

References

Mantovani A, Giavazzi R, Alessandri G, Spreafico F, Garattini S . Characterization of tumor lines derived from spontaneous metastases of a transplanted murine sarcoma. Eur J Cancer (1965). 1981; 17(1):71-6. DOI: 10.1016/0014-2964(81)90213-9. View

Yuan Y, Qin L, Liu D, Wu R, Mussi P, Zhou S . Genetic screening reveals an essential role of p27kip1 in restriction of breast cancer progression. Cancer Res. 2007; 67(17):8032-42. PMC: 2412956. DOI: 10.1158/0008-5472.CAN-07-0083. View

Kokai Y, Myers J, Wada T, Brown V, LeVea C, Davis J . Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell. 1989; 58(2):287-92. DOI: 10.1016/0092-8674(89)90843-x. View

Goel A, Janknecht R . Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J Biol Chem. 2004; 279(15):14909-16. DOI: 10.1074/jbc.M400036200. View

Magnifico A, Albano L, Campaner S, Campiglio M, Pilotti S, Menard S . Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification. Cancer Res. 2007; 67(11):5308-17. DOI: 10.1158/0008-5472.CAN-06-3936. View

Tong D, Czerwenka K, Heinze G, Ryffel M, Schuster E, Witt A . Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer. Clin Cancer Res. 2006; 12(8):2442-8. DOI: 10.1158/1078-0432.CCR-05-0964. View

Peles E, Levy R, Or E, Ullrich A, Yarden Y . Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. EMBO J. 1991; 10(8):2077-86. PMC: 452891. DOI: 10.1002/j.1460-2075.1991.tb07739.x. View

Giannopoulou I, Mylona E, Kapranou A, Mavrommatis J, Markaki S, Zoumbouli C . The prognostic value of the topographic distribution of uPAR expression in invasive breast carcinomas. Cancer Lett. 2007; 246(1-2):262-7. DOI: 10.1016/j.canlet.2006.03.003. View

Wang S, Yuan Y, Liao L, Kuang S, Tien J, OMalley B . Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation. Proc Natl Acad Sci U S A. 2008; 106(1):151-6. PMC: 2629242. DOI: 10.1073/pnas.0808703105. View

10.

Press M, Slamon D, Flom K, Park J, Zhou J, Bernstein L . Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002; 20(14):3095-105. DOI: 10.1200/JCO.2002.09.094. View

11.

Muss H, Thor A, Berry D, Kute T, Liu E, Koerner F . c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994; 330(18):1260-6. DOI: 10.1056/NEJM199405053301802. View

12.

Liu Y, El-Ashry D, Chen D, Ding I, Kern F . MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat. 1995; 34(2):97-117. DOI: 10.1007/BF00665783. View

13.

Tan M, Li P, Sun M, Yin G, Yu D . Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene. 2006; 25(23):3286-95. DOI: 10.1038/sj.onc.1209361. View

14.

Nagata Y, Lan K, Zhou X, Tan M, Esteva F, Sahin A . PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004; 6(2):117-27. DOI: 10.1016/j.ccr.2004.06.022. View

15.

Mussi P, Yu C, OMalley B, Xu J . Stimulation of steroid receptor coactivator-3 (SRC-3) gene overexpression by a positive regulatory loop of E2F1 and SRC-3. Mol Endocrinol. 2006; 20(12):3105-19. DOI: 10.1210/me.2005-0522. View

16.

Press M, Bernstein L, Thomas P, Meisner L, Zhou J, Ma Y . HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997; 15(8):2894-904. DOI: 10.1200/JCO.1997.15.8.2894. View

17.

Wang X, Zheng M, Liu G, Xia W, McKeown-Longo P, Hung M . Krüppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion. Cancer Res. 2007; 67(15):7184-93. DOI: 10.1158/0008-5472.CAN-06-4729. View

18.

Ranson M, Andronicos N . Plasminogen binding and cancer: promises and pitfalls. Front Biosci. 2003; 8:s294-304. DOI: 10.2741/1044. View

19.

Vetter M, Blumenthal S, Lindemann R, Manns J, Wesselborg S, Thomssen C . Ets1 is an effector of protein kinase Calpha in cancer cells. Oncogene. 2004; 24(4):650-61. DOI: 10.1038/sj.onc.1208234. View

20.

Leonard D, Hill A, Kelly L, Dijkstra B, McDermott E, OHiggins N . Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer. Br J Surg. 2002; 89(3):262-71. DOI: 10.1046/j.0007-1323.2001.02022.x. View